Skip to main content
. 2011 Feb;2(2):151–159. doi: 10.1177/1947601911409744

Figure 1.

Figure 1.

Andrographolide inhibits androgen receptor (AR) expression. (A) Dose-dependent inhibition by andrographolide. C4-2 cells were treated with different concentrations of andrographolide for 24 hours in fetal bovine serum (FBS) condition. Total RNAs were isolated for qRT-PCR analysis of AR mRNA expression. (B) C4-2 cells were treated with 20 µM andrographolide at different time points as indicated. Total RNAs were isolated for qRT-PCR analysis of AR mRNA expression. (C) Andrographolide inhibits AR protein expression. C4-2 cells were treated with different concentrations of andrographolide with different time points as indicated. Whole-cell lysates were collected and subjected to Western blot analysis using the antibodies as indicated. (D) Andrographolide inhibits AR protein expression in LNCaP cells. LNCaP cells were treated with different doses of andrographolide, and whole-cell lysates were subjected to Western blot analysis. (E) Andrographolide inhibits AR protein expression in CWR22Rv1 cells. (F) Andrographolide inhibits AR promoter luciferase activity. C4-2 cells were transfected with AR promoter-driven luciferase reporter and treated with different doses of andrographolide. Luciferase activity was measured.